C4PAIN ApS: Financial statements 2023
CVR: 32292402
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
C4PAIN ApS (CVR 32292402) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 27,665 and a net result of DKK 96,580 compared with DKK 237,464 the year before. That is a decrease of 89% compared with the year before. Equity in the 2023 report amounted to DKK 2,904,256. The solvency ratio was 97.6%.
- Gross Profit
- DKK 27,665
- Profit/Loss
- DKK 96,580
- Equity
- DKK 2,904,256
- Total Assets
- DKK 2,974,992
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 28 t. | 97 t. | 2.9 mio. | - |
| 2022 | - | 252 t. | 237 t. | 2.8 mio. | - |
| 2021 | - | 53 t. | 70 t. | 2.6 mio. | - |
| 2020 | - | 658 t. | 542 t. | 2.5 mio. | - |
| 2019 | - | 474 t. | 400 t. | 2 mio. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
C4PAIN ApS has published its annual report for 2022. Gross profit came to DKK 252,356, and the net result was DKK 237,464.
About C4PAIN ApS
C4PAIN ApS is a Danish company of the type Anpartsselskab based in Aalborg, founded in 2009. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Lars Arendt-Nielsen. The company is owned by BIO-MEDICAL CONSULT HOLDING ApS. The company has 0 employees (2014). In 2025, the company reported a gross profit of DKK 159,243 and a net result of DKK 185,909 compared with DKK 1,074,600 the year before. Equity in the 2025 report amounted to DKK 4,164,765.